The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects

Protease-activated receptor-2 (PAR2) is involved in inflammatory responses and pain, therefore representing a promising therapeutic target for the treatment of immune-mediated inflammatory diseases. However, as for other GPCRs, PAR2 can activate multiple signaling pathways and those involved in inflammatory responses remain poorly defined. Here, we describe a new selective and potent PAR2 inhibitor (I-287) that shows functional selectivity by acting as a negative allosteric regulator on Gαq and Gα12/13 activity and their downstream effectors, while having no effect on Gi/o signaling and βarrestin2 engagement. Such selective inhibition of only a subset of the pathways engaged by PAR2 was found to be sufficient to block inflammation in vivo. In addition to unraveling the PAR2 signaling pathways involved in the pro-inflammatory response, our study opens the path toward the development of new functionally selective drugs with reduced liabilities that could arise from blocking all the signaling activities controlled by the receptor.


Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection BRET, fluorescence and luminescence were measured on TriStar² LB 942 Multimode Microplate Reader (Berthold Technologies), FlexStation II microplate reader (Molecular Devices) and SpectraMax L (Molecular Devices), respectively. Western blots detection was performed using a ChemiDoc MP Imaging System (BioRad).

Data analysis
In vitro and in vivo assays were analysed using GraphPad Prism. Relative densitometry analysis on protein bands for western blots was performed using MultiGauge software (Fujifilm).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The authors declare that all data supporting the findings in this study are presented within the article and its Supplementary Information files. The data that support the findings of this study are available from the corresponding author upon reasonable request.

nature research | reporting summary
April 2020 Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
For in vitro experiments, data were repeated independently at least three (3) times. For in vivo experiments, no specific statistical method was used to calculate sample size. The sample size selected was based on previous experiences with the same assays and are in line with the state of the art for similar assays.
Data exclusions Some data were excluded for Fig 2e (calcium experiments) because of drug distribution problems by the instrument. Also, some values are absent (Fig 2k and 5e) from certain replicates because these concentrations were not tested.

Replication
For all cellular assays the experiments were repeated at least three times on different days. For the animal studies, the individual experiments were repeated on different days and were reproducible.
Randomization For cellular experiments, the cells used for the studies came from the same pool of cells that were then distrubuted randmomly in the different experimental groups. Similarly, the mice used in the studies came from the same colony and were split randomly between the experimental groups.

Blinding
The investigators were blinded to group allocation during compounds administration to mice in the in vivo experiments.

Ethics oversight
All procedures were performed in accordance with the Canadian Council on Animal Care (CCAC) and with the International Association for the Study of Pain (IASP) guidelines for pain research on animals. Procedures were also approved by the local Animal Care Committee at the Université de Sherbrooke and were part of protocol 242-14.
Note that full information on the approval of the study protocol must also be provided in the manuscript.